Long-Term Survival With Pembrolizumab for Advanced Melanoma
Posted: Thursday, March 22, 2018
Pembrolizumab may provide long-term survival benefits for patients with ipilimumab-naive and ipilimumab-treated advanced melanoma, according to 3-year overall survival data from the KEYNOTE-001 trial published in the Journal of Clinical Oncology. These phase Ib findings were presented by Caroline Robert, MD, PhD, Head of the Dermatology Unit at the Gustave-Roussy Institute, Paris, and colleagues.
“These data support the use of pembrolizumab in patients with advanced melanoma regardless of prior treatment,” they declared.
Researchers collected data from 655 enrolled patients over a 3-year span, dividing enrollees into ipilimumab-naive and ipilimumab-treated cohorts. Of the patients, 24% had BRAF V600 mutation, 78% had stage M1c disease, 38% had elevated lactate dehydrogenase levels, 75% had had at least one prior therapy, and 52% had received prior ipilimumab treatment.
After 36 months, patients had an overall survival rate of 40%, with a median overall survival of 23.8 months. Overall survival rates after 36 months were 41% in both ipilimumab-treated and ipilimumab-naive patients and 45% in treatment-naive patients.
In previous KEYNOTE trials, pembrolizumab yielded superior progression-free survival over chemotherapy in ipilimumab-refractory melanoma (KEYNOTE-002) as well as progression-free and overall survival over ipilimumab in advanced melanoma (KEYNOTE-006).